Performance Evaluation Methods for Recombinant Protein Raw Materials in In Vitro Diagnostic Reagents

Functional Positioning of Recombinant Proteins in In Vitro Diagnostics

The core reactions of in vitro diagnostic reagents often rely on key biological raw materials such as antigens, antibodies, enzymes, or standards. Recombinant proteins, prepared through genetic engineering, can serve in in vitro diagnostics as capture antigens, calibrator or quality control components in immunoassays, and can also be used as coating antigens or labeled antigens in antibody detection reagents. Their amino acid sequences are well-defined and their sources are clear, which facilitates stable control of reagent performance.

Compared with native proteins, recombinant proteins are more easily subjected to molecular design to remove cross-reactive epitopes or introduce specific tags, thereby enhancing detection specificity. However, in practical applications, whether the active epitopes of recombinant proteins are intact and whether their spatial conformation is close to the native state directly affects detection sensitivity and correlation with clinical samples.

Activity and Purity Assessment

For diagnostic recombinant proteins, functional validation generally needs to be carried out in combination with the specific detection platform. For example, on chemiluminescence or enzyme-linked immunosorbent assay platforms, signal linearity and discriminatory ability can be observed by gradient dilution combined with known positive or negative samples. Activity assessment should not rely solely on total protein concentration; greater attention should be paid to specific activity or the effective binding capacity per unit mass of protein.

In terms of purity, methods such as SDS-PAGE, high-performance liquid chromatography, or mass spectrometry should be used to examine the proportion of the target band, degradation fragments, and aggregate content. Common diagnostic raw materials have certain purity requirements, but specific limits should be determined in combination with process feasibility and the final performance of the reagent, and it is not advisable to simply pursue a single indicator.

Batch-to-Batch Consistency and Stability

In vitro diagnostic products require long-term stable supply, so batch-to-batch consistency of recombinant protein raw materials is crucial. Generally, standardized operating procedures are established for each stage from fermentation or culture, purification, to lyophilization and preservation, and key process parameters are recorded and controlled. Batch-to-batch consistency can be compared through multi-dimensional data such as activity, purity, appearance, and moisture content.

In terms of stability, the activity retention rate, changes in physical state, and microbiological indicators are usually examined under accelerated conditions and long-term storage conditions. For raw materials preserved in liquid form, attention should also be paid to the effects of repeated freeze-thaw cycles and temperature fluctuations during transportation. Suppliers should be able to provide corresponding stability data and storage recommendations to facilitate the assessment of shelf-life risks by diagnostic reagent companies.

Supply Chain and Regulatory Compliance

When selecting recombinant protein raw materials, in vitro diagnostic reagent manufacturers need to pay attention not only to technical performance but also to the supplier's quality management system, change notification, document completeness, and traceability. For products involving medical device registration, changes in key attributes of raw materials may trigger registration changes or performance verification requirements.

Overall, the application value of recombinant proteins in in vitro diagnostics needs to be supported by evidence from multiple aspects such as activity, purity, consistency, and stability, rather than merely completing protein expression. Establishing a scientific evaluation framework helps reduce reagent development risks and improve quality stability after product launch.